Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FUJRS
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,780
Award facts
- Contract value 100% obligated
- $19,779.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order for Entyvio 300 mg vials valued at $19.78K by the Defense Logistics Agency. The award, issued on August 25, 2025, with an ultimate completion date of September 16, 2025, represents a firm fixed-price contract with no set-aside designation. Entyvio (vedolizumab) is a biologic immunosuppressant medication primarily used to treat inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies for Department of Defense healthcare facilities worldwide.
As a woman-owned small business with extensive federal contracting experience since its SAM.gov registration in 2001, DMS Pharmaceutical Group has established itself as a critical supplier in the federal pharmaceutical supply chain. The company's portfolio encompasses branded and generic prescription drugs, biologics, over-the-counter medications, and specialized pharmaceutical products distributed to military and federal healthcare systems. The delivery order will be fulfilled at the company's headquarters location in Park Ridge, Illinois, continuing DMS Pharmaceutical Group's consistent track record of providing timely pharmaceutical supply solutions to support Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DB25FUJRS?
SPE2DB25FUJRS was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 25, 2025.
How much is contract SPE2DB25FUJRS worth?
The government has obligated $19,780 on SPE2DB25FUJRS.
Is contract SPE2DB25FUJRS an order under another contract?
Yes. SPE2DB25FUJRS is a delivery order under SPE2DB25D9365, an indefinite delivery contract.
Was contract SPE2DB25FUJRS competed?
The extent of competition for SPE2DB25FUJRS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award